Orion Infusion reports per share loss Tk 192

Investors have incurred significant losses per share in Orion Infusion, one of the country's leading companies in the pharmaceutical and chemical sectors.

The investors have lost Tk 191.60 per share in the last three and a half months.

Previously, the company announced issuing a right share at the end of the last year, causing the share price to reach its highest point.

However, the company has yet to complete issuing its rights shares. Company officials believe that investors are losing interest in the company's shares due to the delay in the issuance.

According to the Dhaka Stock Exchange (DSE), the company's price per share was Tk 709.50 on February 18, which fell to Tk 517.90 on Wednesday.

The share price decreased by Tk 191.60 or 27 percent. Currently, the company's share price continues to fall.

In November 2023, the company announced the issuance of rights shares. Within three months, the company's share price jumped to the highest position of the year.

The share price was Tk 290.70 on November 28, 2023, and rose to Tk 709.50 on February 18, marking an increase of 144 percent.

In November last year, the company announced a raise in paid-up capital through a right share issuance. Since then, the price of the company's shares has started to increase.

The board of Orion Infusion has decided to issue rights shares in the ratio of 2:1. That means the company will issue one right share for every two existing shares.

The issue price of each share will be Tk 20, including a premium of Tk 10.

The company also mentioned that they were seeking approval from the regulatory body BSEC and other authorities concerned.

Around six months have passed but Orion Infusion has still not issued the right shares as a result the company's share price has been falling for the last three months.

While talking to the reporter, Orion Infusion Company Secretary Md. Habibur Rahman said that the share price fluctuations depend on the needs of investors.

There is no specific reason for the decline in the company's share prices. However, the delay in issuing the right shares may have impacted the share price.

An analysis of the company's financial report shows that the company's earnings per share (EPS) for the third quarter from January-March of the financial year 2023-24 was 39 paise while the warning was 38 paise during the same period of the last year.

And, for three quarters from July 23 to March 24, the company earned T1.5 per share while the earnings were T1.41 during the same period last year. The company's net asset value per share (NAVPS) as of March 31, 2024 was Tk 14.92.

The company has decided to pay a 10 percent cash dividend to the investors for the financial year ending June 30, 2023.

The EPS of Orion Infusion was Tk 2.6 in the current financial year, compared to Tk 2.10 in the previous financial year. The NAVPS of the company at the end of June 30, 2023, stood at Tk 14.32.

Earlier, Orion Infusion paid a 20 percent cash dividend to shareholders for the financial year ended 2021-22.

In the financial year under review, the company's EPS has been Tk 2.10, which was Tk 1.37 in the same period of the previous year.

The NAVPS of the company at the end of June 30, 2022, stood at Tk 14.22, which was Tk 13.10 at the end of the previous financial year.